If You Invested in 180 Life Sciences Corp (ATNF)
Looking for the live price? See the ATNF quote & overviewWhat $1,000 or $10,000 in ATNF Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jun 28, 2017 |
|---|---|---|---|---|
| $1,000 | $8,374 +737% | $2 -100% | — | $2 -100% |
| $10,000 | $83,740 +737% | $19 -100% | — | $19 -100% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for ATNF$1,000 Investment Over Time
ATNF vs S&P 500Year-by-Year Returns
ATNF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $3686.00 | $3689.80 | +0.1% | +0.1% |
| 2018 | $3689.80 | $3876.00 | +5.0% | +5.2% |
| 2019 | $3869.16 | $4063.72 | +5.0% | +10.2% |
| 2020 | $4063.72 | $1037.40 | -74.5% | -71.9% |
| 2021 | $953.80 | $1482.00 | +55.4% | -59.8% |
| 2022 | $1432.60 | $64.41 | -95.5% | -98.3% |
| 2023 | $100.70 | $4.06 | -96.0% | -99.9% |
| 2024 | $3.91 | $1.82 | -53.4% | -100.0% |
| 2025 | $1.72 | $7.04 | +309.3% | -99.8% |
About 180 Life Sciences Corp
Pharmaceutical Preparations · NASDAQ
ATNF historically represented 180 Life Sciences Corp. on the Nasdaq Capital Market. According to company disclosures, 180 Life Sciences began as an innovative biotechnology company and later pivoted its business toward the global interactive technology and iGaming sector, while retaining a portfolio of legacy biotechnology intellectual property assets. More recently, the company has further evolved by adopting an Ethereum (ETH) treasury strategy and rebranding to operate as ETHZilla, with plans for its stock to trade under the ticker ETHZ on Nasdaq, replacing ATNF.
The company describes itself as developing an accumulation vehicle for Ether (ETH), the native digital asset of the Ethereum blockchain. Through a treasury policy focused on ETH, it aims to hold Ether as the principal asset in its treasury reserve. Public disclosures explain that the company intends to allocate significant capital raised through private placements and convertible notes to purchase ETH and related yield-bearing assets, while also supporting its iGaming operations and working to monetize its legacy biotech intellectual property.
In connection with this strategy, the company has engaged Electric Capital as an external asset manager. Company statements describe plans for a differentiated, on-chain yield generation program that seeks to outperform traditional ETH staking by using a combination of staking, lending, liquidity provisioning and bespoke private agreements, subject to risk management. The company also refers to guidance from a DeFi Council composed of capital markets participants, Ethereum engineers, and decentralized finance founders, intended to help shape its treasury approach.
Alongside its digital asset treasury activities, the company has indicated that it is evolving its business toward software-enabled gaming and entertainment. It reports having acquired a proprietary Technology Gaming Platform described as a back-end system that allows operation of one or more online casinos. Public communications state that the company is focused on evaluating acquisitions or development of online casino and related entertainment businesses that would run on this platform, while it continues to refine and deploy its gaming initiatives.
Despite these pivots, 180 Life Sciences emphasizes the ongoing importance of its legacy biotechnology IP estate. Company announcements highlight patents and patent applications in therapeutic areas such as post-operative cognitive decline, neuroinflammation, and fibrosis. For example, the company has disclosed a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering a method for preventing or reducing post-operative cognitive dysfunction using an anti-human tumor necrosis factor (TNF) alpha monoclonal antibody, and separate protection related to localized fibrotic disorders, including Dupuytren's Disease and Frozen Shoulder, through an IL-33 antagonist.
In more recent communications under the ETHZilla brand, the company states that it intends to focus a significant portion of its non-legacy operations on becoming an ETH accumulation vehicle built for the Ethereum community. It describes an ambition to become a benchmark for on-chain treasury management among public companies, while continuing to support its iGaming operations and seeking to realize value from its biotechnology intellectual property through potential partnering, licensing, or strategic transactions.
Investors researching ATNF should understand that this ticker is historically associated with 180 Life Sciences and its transition phases: from clinical-stage biotechnology, to a biotechnology company pivoting into iGaming, and then to a company implementing an Ethereum-focused treasury strategy and rebranding as ETHZilla. Company materials indicate that, as part of this evolution, the common stock and public warrants are expected to trade on Nasdaq under new symbols ETHZ and ETHZW, replacing ATNF and ANTFW.
Business evolution and segments
Based on company disclosures, the business can be viewed in three main areas:
- ETH treasury and digital asset strategy: Adoption of a treasury policy centered on Ether, use of proceeds from private placements and convertible notes to purchase ETH and yield-bearing assets, and collaboration with Electric Capital on on-chain yield strategies.
- Software-enabled gaming and iGaming: Focus on the global iGaming sector, leveraging a proprietary Technology Gaming Platform to operate or support online casino and related entertainment businesses, with attention to cryptocurrency and blockchain-related trends in gaming.
- Legacy biotechnology intellectual property: Maintenance and enhancement of a portfolio of biotech IP in areas such as anti-TNF therapies, post-operative cognitive decline, neuroinflammation, and fibrotic disorders, with stated intent to explore partnering, licensing, or other strategic options.
These activities reflect a company that has moved beyond its original biotechnology focus into digital entertainment and digital asset treasury management, while still emphasizing the potential value of its scientific IP.
ATNF ticker and transition to ETHZ
Press releases note that the company, doing business as ETHZilla, plans to rebrand formally as ETHZilla Corporation and that its common stock and public warrants will begin trading on the Nasdaq Capital Market under the new ticker symbols ETHZ and ETHZW, replacing the previous symbols ATNF and ANTFW. For users researching ATNF, this means that historical information under ATNF relates to 180 Life Sciences and its transformation, while current and future trading and disclosures may appear under ETHZ.
Legacy biotech focus areas
In earlier descriptions and subsequent IP-related announcements, the company has described work and intellectual property in:
- Inflammatory diseases and fibrosis: Including anti-TNF platforms and approaches to localized fibrotic disorders such as Dupuytren's Disease and Frozen Shoulder.
- Neuroinflammation and post-operative cognitive decline: Methods and agents aimed at preventing or reducing cognitive impairment following surgery or other inflammatory triggers, including use of anti-TNF monoclonal antibodies.
These legacy assets are characterized by the company as potential contributors to long-term shareholder value, even as operational focus shifts toward gaming and Ethereum-related activities.
Sector classification
In industry classification terms, ATNF has been associated with pharmaceutical preparation manufacturing within the broader manufacturing sector, reflecting its biotechnology origins. However, company communications also describe a pivot to the international entertainment and iGaming sector and the development of an ETH-focused treasury strategy, so the business profile spans biotechnology, gaming technology, and digital asset treasury management.
FAQs about ATNF / 180 Life Sciences / ETHZilla
Similar Stocks
See how related companies performed
Frequently Asked Questions
180 Life Sciences Corp investment returns
How much would $1,000 invested in 180 Life Sciences Corp be worth today?
If you invested $1,000 in 180 Life Sciences Corp (ATNF) 5 years ago on 2021-07-09, your investment would be worth $2 today, representing a -99.8% total return, growing at a compounded rate of -78.4% per year (CAGR).
Has 180 Life Sciences Corp outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare ATNF performance over available time periods.
What is 180 Life Sciences Corp's average annual return?
The compound annual growth rate (CAGR) of ATNF over the past 5 years is -78.4%, growing at a compounded rate each year. Individual years vary significantly — ATNF's best recent year was 2025 (+309.3%) and worst was 2023 (-96.0%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
